$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

Published by Current Partnering: 01 Oct 2016 | 370 | In Stock

Introduction

The Global Cancer Diagnostics Partnering 2010-2016 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in cancer diagnostics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer diagnostics partnering contract documents

Top cancer diagnostics deals by value


This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2010.


The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.


The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 1,170 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.


Key benefits


Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:


In-depth understanding of Cancer Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies

Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies

Identify most active Cancer Diagnostics dealmakers since 2010

Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.


Cancer Diagnostics Partnering Terms and Agreements includes:


Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Cancer Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Cancer Diagnostics deals

Access to Cancer Diagnostics contract documents

Leading Cancer Diagnostics deals by value since 2010

Most active Cancer Diagnostics dealmakers since 2010


In Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,170 Cancer Diagnostics deals.


Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in Cancer Diagnostics dealmaking

    2.1. Introduction

    2.2. Cancer Diagnostics partnering over the years

    2.3. Most active Cancer Diagnostics dealmakers

    2.4. Cancer Diagnostics partnering by deal type

    2.5. Cancer Diagnostics partnering by therapy area

    2.6. Deal terms for Cancer Diagnostics partnering

    2.6.1 Cancer Diagnostics partnering headline values

    2.6.2 Cancer Diagnostics deal upfront payments7

    2.6.3 Cancer Diagnostics deal milestone payments

    2.6.4 Cancer Diagnostics royalty rates

    Chapter 3 – Leading Cancer Diagnostics deals

    3.1. Introduction

    3.2. Top Cancer Diagnostics deals by value

    Chapter 4 – Most active Cancer Diagnostics dealmakers

    4.1. Introduction

    4.2. Most active Cancer Diagnostics dealmakers

    4.3. Most active Cancer Diagnostics partnering company profiles

    Chapter 5 – Cancer Diagnostics contracts dealmaking directory

    5.1. Introduction

    5.2. Cancer Diagnostics contracts dealmaking directory

    Chapter 6 – Cancer Diagnostics dealmaking by technology type

    Chapter 7 – Partnering resource center

    7.1. Online partnering

    7.2. Partnering events

    7.3. Further reading on dealmaking

    Appendices

    Appendix 1 – Cancer Diagnostics deals by company A-Z

    Appendix 2 – Cancer Diagnostics deals by stage of development

    Discovery

    Preclinical

    Phase I

    Phase II

    Phase III

    Regulatory

    Marketed

    Formulation

    Appendix 3 – Cancer Diagnostics deals by deal type

    Asset purchase

    Assignment

    Bigpharma outlicensing

    Co-development

    Collaborative R&D

    Co-market

    Co-promotion

    CRADA

    Cross-licensing

    Development

    Distribution

    Equity purchase

    Evaluation

    Grant

    Joint venture

    Licensing

    Litigation

    Manufacturing

    Marketing

    Material transfer

    Option

    Promotion

    Research

    Settlement

    Spin out

    Sub-license

    Supply

    Technology transfer

    Termination

    Warranty

    Appendix 4 – Cancer Diagnostics deals by therapy area

    Appendix 5 –Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    Table of figures

    Figure 1: Cancer Diagnostics partnering since 2010

    Figure 2: Active Cancer Diagnostics dealmaking activity– 2010 to 2016

    Figure 3: Cancer Diagnostics partnering by deal type since 2010

    Figure 4: Cancer Diagnostics partnering by disease type since 2010

    Figure 5: Cancer Diagnostics deals with a headline value

    Figure 6: Cancer Diagnostics deals with an upfront value

    Figure 7: Cancer Diagnostics deals with a milestone value

    Figure 8: Cancer Diagnostics deals with a royalty rate value

    Figure 9: Top Cancer Diagnostics deals by value since 2010

    Figure 10: Most active Cancer Diagnostics dealmakers 2010 to 2016

    Figure 11: Online partnering resources

    Figure 12: Forthcoming partnering events

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

370 | CP22013

Number of Pages

696

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?
Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
28 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info
The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
01 Jul 2014 by FirstWord Pharma USD $4,995 More Info
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
28 Apr 2014 by FirstWord Pharma USD $695 More Info
Breast Cancer: New targeted therapies transform treatment - KOL Insight
IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
10 Feb 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
KOL Insight: Prostate Cancer: Competition intensifies in race to the top
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
01 Nov 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
01 Nov 2013 by FirstWord Pharma USD $4,995 More Info
Colorectal Cancer -- KOL Insight Module
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
01 Oct 2013 by FirstWord Pharma USD $7,900 More Info
Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data